Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Rating of "Buy" from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has earned an average rating of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $202.29.

Several analysts have issued reports on the company. HC Wainwright restated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Citigroup lifted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Evercore ISI lifted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 14.10% of the company's stock.

Institutional Trading of Krystal Biotech

Several hedge funds have recently added to or reduced their stakes in the business. Summit Trail Advisors LLC acquired a new position in shares of Krystal Biotech during the third quarter valued at approximately $1,893,000. Swiss National Bank increased its position in shares of Krystal Biotech by 8.0% during the 3rd quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $7,117,000 after purchasing an additional 2,900 shares during the period. Sei Investments Co. increased its position in shares of Krystal Biotech by 18.9% during the 2nd quarter. Sei Investments Co. now owns 40,115 shares of the company's stock valued at $7,367,000 after purchasing an additional 6,363 shares during the period. Shaker Investments LLC OH bought a new stake in shares of Krystal Biotech in the 3rd quarter worth $532,000. Finally, Citigroup Inc. lifted its holdings in shares of Krystal Biotech by 65.4% in the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock valued at $6,386,000 after buying an additional 13,874 shares during the period. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

Shares of KRYS stock traded up $5.49 during mid-day trading on Friday, reaching $185.25. 216,765 shares of the company were exchanged, compared to its average volume of 229,305. The business's 50 day simple moving average is $181.27 and its 200 day simple moving average is $184.52. The company has a market capitalization of $5.33 billion, a P/E ratio of 104.66 and a beta of 0.80. Krystal Biotech has a fifty-two week low of $101.34 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the firm earned ($0.67) EPS. The company's revenue was up 879.9% on a year-over-year basis. On average, analysts forecast that Krystal Biotech will post 2.97 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).